154 related articles for article (PubMed ID: 1699283)
21. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
[TBL] [Abstract][Full Text] [Related]
22. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
23. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
Robertson LE; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Plunkett W; Keating MJ
Leukemia; 1995 Sep; 9(9):1444-9. PubMed ID: 7658710
[TBL] [Abstract][Full Text] [Related]
24. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response.
Angelopoulou MA; Poziopoulos C; Boussiotis VA; Kontopidou F; Pangalis GA
Leuk Lymphoma; 1996 Apr; 21(3-4):321-4. PubMed ID: 8726414
[TBL] [Abstract][Full Text] [Related]
26. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.
Sorensen JM; Vena DA; Fallavollita A; Chun HG; Cheson BD
J Clin Oncol; 1997 Feb; 15(2):458-65. PubMed ID: 9053466
[TBL] [Abstract][Full Text] [Related]
27. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
Keating MJ; Kantarjian H; Talpaz M; Redman J; Koller C; Barlogie B; Velasquez W; Plunkett W; Freireich EJ; McCredie KB
Blood; 1989 Jul; 74(1):19-25. PubMed ID: 2473795
[TBL] [Abstract][Full Text] [Related]
28. Fludarabine shows promise for some leukemia patients.
Oncology (Williston Park); 1989 Mar; 3(3):14. PubMed ID: 2484283
[No Abstract] [Full Text] [Related]
29. [Fludarabine monophosphate in the treatment of patients with advanced stages of chronic B-cell lymphatic leukemia resistant to conventional chemotherapy].
Papajík T; Faber E; Hubácek J; Slezák P; Raida L; Heczko M; Sulovská I; Jarosová M; Pikalová Z; Indrák K
Vnitr Lek; 1997 Jan; 43(1):25-8. PubMed ID: 9221561
[TBL] [Abstract][Full Text] [Related]
30. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
[TBL] [Abstract][Full Text] [Related]
31. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.
Puccio CA; Mittelman A; Lichtman SM; Silver RT; Budman DR; Ahmed T; Feldman EJ; Coleman M; Arnold PM; Arlin ZA
J Clin Oncol; 1991 Sep; 9(9):1562-9. PubMed ID: 1714949
[TBL] [Abstract][Full Text] [Related]
32. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
[TBL] [Abstract][Full Text] [Related]
33. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
Foran JM; Rohatiner AZ; Coiffier B; Barbui T; Johnson SA; Hiddemann W; Radford JA; Norton AJ; Tollerfield SM; Wilson MP; Lister TA
J Clin Oncol; 1999 Feb; 17(2):546-53. PubMed ID: 10080598
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
35. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Leporrier M; Chevret S; Cazin B; Boudjerra N; Feugier P; Desablens B; Rapp MJ; Jaubert J; Autrand C; Divine M; Dreyfus B; Maloum K; Travade P; Dighiero G; Binet JL; Chastang C;
Blood; 2001 Oct; 98(8):2319-25. PubMed ID: 11588025
[TBL] [Abstract][Full Text] [Related]
36. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
O'Brien S; Kantarjian H; Beran M; Robertson LE; Koller C; Lerner S; Keating MJ
Blood; 1995 Aug; 86(4):1298-300. PubMed ID: 7632936
[TBL] [Abstract][Full Text] [Related]
37. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
39. Chronic lymphocytic leukemia--correlation of response and survival.
Keating MJ; O'Brien S; Robertson L; Huh Y; Kantarjian H; Plunkett W
Leuk Lymphoma; 1993; 11 Suppl 2():167-75. PubMed ID: 8124227
[TBL] [Abstract][Full Text] [Related]
40. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis.
Robertson LE; Huh YO; Butler JJ; Pugh WC; Hirsch-Ginsberg C; Stass S; Kantarjian H; Keating MJ
Blood; 1992 Jul; 80(1):29-36. PubMed ID: 1377051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
